	US 12,440,546 B2
	Composition for preventing or treating benign tumor
Haruo Sugiyama, Minoo (JP)
Assigned to International Institute of Cancer Immunology, Inc., Suita (JP)
Appl. No. 17/282,172
Filed by International Institute of Cancer Immunology, Inc., Suita (JP)
PCT Filed Oct. 4, 2019, PCT No. PCT/JP2019/039383 § 371(c)(1), (2) Date Apr. 1, 2021, PCT Pub. No. WO2020/071551, PCT Pub. Date Apr. 9, 2020.
Claims priority of application No. 2018-190461 (JP), filed on Oct. 5, 2018.
Prior Publication US 2022/0008528 A1, Jan. 13, 2022
Int. Cl. A61K 39/00 (2006.01); A61K 35/15 (2025.01); A61K 35/17 (2025.01); A61K 39/39 (2006.01); A61P 35/00 (2006.01); C12N 5/0784 (2010.01)

CPC A61K 39/001153 (2018.08) [A61K 35/15 (2013.01); A61K 35/17 (2013.01); A61K 39/39 (2013.01); A61P 35/00 (2018.01); C12N 5/0639 (2013.01); A61K 2039/53 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55566 (2013.01); C12N 2501/415 (2013.01)]

28 Claims

1. A method for treating a benign tumor expressing WT1 selected from the group consisting of familial adenomatous polyposis, non-hereditary colorectal adenoma, intraductal papillary mucinous neoplasm, meningioma, schwannoma, epithelial adenoma of an organ, papilloma, non-epithelial myoma, lipoma, and chondroma in a subject, the method comprising:

administering to the subject an effective amount of a peptide selected from the group consisting of

RMFPNAPYL of SEQ ID NO: 2,

RYFPNAPYL of SEQ ID NO: 46,

YMFPNAPYL of SEQ ID NO: 14,

CYTWNOMNL of SEQ ID NO: 45,

CMTWNQMNL of SEQ ID NO: 3,

C-CYTWNQMNL of SEQ ID NO: 47 wherein C-C shown in the formula means that the C residues are linked together by a disulfide bond, and

C-CMTWNQMNL of SEQ ID NO: 48 wherein C-C shown in the formula means that the C residues are linked together by a disulfide bond.